ArticleBritish journal of cancer2013
DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Ovarian Cancer-SpecificClinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Tissue-Specific Prevalence and Clonal Architecture ofbioRxiv : the preprint server for biology · 2026Article
- Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesis.EBioMedicine · 2026Article
- BRCA2 C-terminal clamp restructures RAD51 dimers to bind B-DNA for replication fork stability.Molecular cell · 2025Article
- CINner: Modeling and simulation of chromosomal instability in cancer at single-cell resolution.PLoS computational biology · 2025Article
- Deletions Rate-Limit Breast and Ovarian Cancer Initiation.bioRxiv : the preprint server for biology · 2024Article
- CINner: modeling and simulation of chromosomal instability in cancer at single-cell resolution.bioRxiv : the preprint server for biology · 2024Article
- Modeling High-Grade Serous Ovarian Carcinoma Using a Combination ofCancer research · 2021Article
- Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.Genetics and molecular biology · 2019Article
- Sulforaphane regulates apoptosis- and proliferation‑related signaling pathways and synergizes with cisplatin to suppress human ovarian cancer.International journal of molecular medicine · 2018Article
- Genetic alterations detected by comparative genomic hybridization in BRCAX breast and ovarian cancers of Brazilian population.Oncotarget · 2018Article
- BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.Nature communications · 2017Article
- Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.Oncotarget · 2016Article
- DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers.Oncotarget · 2016Article
- Melatonin Suppresses the Growth of Ovarian Cancer Cell Lines (OVCAR-429 and PA-1) and Potentiates the Effect of G1 Arrest by Targeting CDKs.International journal of molecular sciences · 2016Article
- The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.Journal of gynecologic oncology · 2016Article
- WWOX CNV-67048 Functions as a Risk Factor for Epithelial Ovarian Cancer in Chinese Women by Negatively Interacting with Oral Contraceptive Use.BioMed research international · 2016Article
- Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.Molecular oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew studies have attempted to characterise genomic changes occurring in hereditary epithelial ovarian carcinomas (EOCs) and inconsistent results have been obtained. Given the relevance of DNA copy number alterations in ovarian oncogenesis and growing clinical implications of the BRCA-gene status, we aimed to characterise the genomic profiles of hereditary and sporadic ovarian tumours.
methodsHigh-resolution array Comparative Genomic Hybridisation profiling of 53 familial (21 BRCA1, 6 BRCA2 and 26 non-BRCA1/2) and 15 sporadic tumours in combination with supervised and unsupervised analysis was used to define common and/or specific copy number features.
resultsUnsupervised hierarchical clustering did not stratify tumours according to their familial or sporadic condition or to their BRCA1/2 mutation status. Common recurrent changes, spanning genes potentially fundamental for ovarian carcinogenesis, regardless of BRCA mutations, and several candidate subtype-specific events were defined. Despite similarities, greater contribution of losses was revealed to be a hallmark of BRCA1 and BRCA2 tumours.
conclusionSomatic alterations occurring in the development of familial EOCs do not differ substantially from the ones occurring in sporadic carcinomas. However, some specific features like extensive genomic loss observed in BRCA1/2 tumours may be of clinical relevance helping to identify BRCA-related patients likely to respond to PARP inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.